EUVIMEDEUVIMED entdecken
Crossref

Association of propranolol with treatment-emergent akathisia during aripiprazole treatment

Ádám Menus iD, Ádám Kiss, Gábor Csukly iD, István Bitter iD, Katalin Monostory iD, János M Réthely iD

Ideggyógyászati szemle · 2025

DOI: 10.18071/isz.78.0395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ideggyógyászati szemle, 2025. Verfasst von Ádám Menus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Semmelweis University, Department of Psychiatry and Psychotherapy, Budapest. Hauptthemen laut MEDLINE: Aripiprazole, Propranolol, Antipsychotic Agents, Adrenergic beta-Antagonists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose – Akathisia is a common side effect of aripiprazole treatment, which is associated with subjective distress for patients, and represents a frequent cause of treatment discontinuation. Propranolol and other beta-receptor blockers are commonly used for treatment of akathisia. Cytochrome P450 2D6 (CYP2D6) enzyme plays a major role in the metabolism of aripiprazole. Our previous study has shown that CYP2D6 inhibitory activity of beta-blockers (metoprolol and propranolol) may result in elevated aripiprazole plasma concentrations. The objective of the present retrospective study was to assess the prevalence of akathisia in patients receiving propranolol or metoprolol comedication, as well as in those not receiving any CYP2D6 inhibitors such as propranolol, metoprolol, risperidone. Methods – Using the data of our previous pharmacogenetic study involving 67 patients diagnosed with schizophrenia or schizoaffective disorder and receiving aripiprazole treatment, we retrospectively investigated the emergence of akathisia within 6 months following aripiprazole initiation. Information on the onset of akathisia was obtained from patients’ medical records. The effects of CYP2D6 genotype, aripiprazole plasma concentration, propranolol and metoprolol comedication on the development of akathisia were analysed. The included patients had already been taking propranolol and metoprolol comedication prior to the initiation of aripiprazole and not for the treatment of akathisia. Results – Schizophrenia and schizoaffective disorder patients treated with propranolol had a significantly higher incidence of documented akathisia (38,5%) compared to the group not receiving CYP2D6 inhibitors (5.9%), and the group treated with metoprolol comedication (7.1%). Among the CYP2D6 inhibitors, only the administration of propranolol increased the risk of akathisia (Wald Chi2=5.5, p=0.02, OR=7.6 [95% CI=1.4-41.4]). The polymorphic CYP2D6 alleles resulting in low CYP2D6 function showed a statistical trend-level association with the occurrence of akathisia (Wald Chi2=2.6, p=0.11, OR=4.7 [95% CI=0.7-30.8]). In a subsequent analysis, we investigated the possible interaction of propranolol and CYP2D6 genotypes on the development of akathisia. The interaction model showed that the effect of propranolol was not dependent on CYP2D6 genotype (Wald Chi2=0.1, p=0.92), however, its independent effect remained significant (Wald Chi2=4.4, p=0.04). Conclusion – Our findings suggest that propranolol comedication increases the risk of the development of akathisia during aripiprazole treatment. It is of paramount importance to avoid propranolol comedication during aripiprazole treatment. However, two major limitations should be considered: akathisia was not assessed using a standardized clinical rating scale, and the majority of patients (80.6%) received antipsychotic combination therapy, which may have influenced the findings. Further prospective studies are needed to confirm these findings based on retrospective, naturalistic analysis about the development of aripiprazole-induced akathisia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazolePropranololAntipsychotic AgentsAdrenergic beta-AntagonistsAkathisia, Drug-InducedHumansRetrospective StudiesMaleFemaleCytochrome P-450 CYP2D6MetoprololAdultMiddle AgedSchizophreniaPsychotic DisordersCytochrome P-450 CYP2D6 Inhibitors

Stichwörter der Autor:innen

CYP2D6 genotypeakathisiaaripiprazolepharmacogeneticsplasma concentrationpropranolol

Substanzen

AripiprazolePropranololCytochrome P-450 CYP2D6Antipsychotic AgentsAdrenergic beta-AntagonistsMetoprololCytochrome P-450 CYP2D6 Inhibitors

Autor:innen und Institutionen

  • Semmelweis University, Department of Psychiatry and Psychotherapy, Budapest.
  • Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest.

ORCID-Profile: Ádám Menus, Gábor Csukly, István Bitter, Katalin Monostory, János M Réthely

Zitieren

APA

Menus, Á., Kiss, Á., Csukly, G., Bitter, I., Monostory, K., & M Réthely, J. (2025). Association of propranolol with treatment-emergent akathisia during aripiprazole treatment. Ideggyógyászati szemle. https://doi.org/10.18071/isz.78.0395

Vancouver

Menus Á, Kiss Á, Csukly G, Bitter I, Monostory K, M Réthely J. Association of propranolol with treatment-emergent akathisia during aripiprazole treatment. Ideggyógyászati szemle. 2025. doi:10.18071/isz.78.0395

BibTeX
@article{Menus2025,
  author = {Menus, Ádám and Kiss, Ádám and Csukly, Gábor and Bitter, István and Monostory, Katalin and M Réthely, János},
  title = {Association of propranolol with treatment-emergent akathisia during aripiprazole treatment},
  journal = {Ideggyógyászati szemle},
  year = {2025},
  doi = {10.18071/isz.78.0395}
}
Kostenlos starten →